{"nctId":"NCT00450437","briefTitle":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults","startDateStruct":{"date":"2007-03"},"conditions":["Meningococcal Infections","Meningococcal Meningitis"],"count":3539,"armGroups":[{"label":"Licensed Meningococcal Vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Meningococcal ACWY Conjugate vaccine"]},{"label":"Novartis MenACWY Conjugate Vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: MenACWY CRM"]}],"interventions":[{"name":"MenACWY CRM","otherNames":[]},{"name":"Meningococcal ACWY Conjugate vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy subjects who are 11-55 years of age inclusive and who have given appropriate written assent and/or consent\n\nExclusion Criteria:\n\n* Subjects with a previous or suspected disease caused by N. meningitidis\n* previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)\n* previous or suspected disease caused by N. meningitidis\n* Any serious acute, chronic or progressive disease\n* Pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"11 Years","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years","description":"The consistency of immune response for the three lots of Meningococcal ACWY (MenACWY), as measured by human serum bactericidal activity (hSBA) geometric mean titer (GMT) response using human complement (hSBA GMTs) directed against N. meningitidis serogroups A, C, W, and Y (healthy subjects 11 to 18 years of age)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Seroresponders, Ages 11 to 18 Years","description":"Immunogenicity of a single injection of Meningococcal ACWY (3 lots pooled) to that of a licensed meningococcal ACWY conjugate vaccine, defined as the percentage of subjects with seroresponse directed against N meningitidis serogroups A, C, W, and Y (healthy adolescents 11 to 18 years of age).\n\nSeroresponse to MenACWY: For a subject with hSBA titer \\<1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 Years","description":"Safety of Novartis Meningococcal ACWY and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of participants presenting at least one severe systemic reaction during the first 7 days (Days 1-7) following a single vaccination.\n\nNote: severe adverse events: unable to perform normal daily activity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Lot to Lot Consistency for the Percentage of Subjects With Seroresponse, Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:8, and ≥ 1:4, Ages 11 to 18 Years","description":"The consistency of the immune response for three lots of Meningococcal ACWY, as measured by the percentage of subjects with seroresponse, hSBA titer ≥ 1:4 and ≥ 1:8, directed against N meningitidis serogroups A, C, W, and Y (healthy adolescents 11 to 18 years of age).\n\nSeroresponse to MenACWY: For a subject with hSBA titer \\<1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Seroresponse, Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:8, and hSBA Titer ≥ 1:4, Ages 11 to 55 Years","description":"Immunogenicity of a single injection of MenACWY (3 lots combined) to that of a licensed meningococcal ACWY conjugate vaccine, defined as the percentage of subjects with seroresponse directed against N meningitidis serogroups A, C, W, and Y (healthy subjects 11 to 55 years of age).\n\nSeroresponse to MenACWY: For a subject with hSBA titer \\<1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers, Ages 11 to 55 Years","description":"Immunogenicity of a single injection of MenACWY (3 lots combined) to that of a single injection of a licensed meningococcal ACWY conjugate vaccine, as measured by hSBA GMTs directed against N meningitidis serogroups A, C, W, and Y (healthy subjects 11 to 55 years of age).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Local and Systemic Reactions, Ages 11 to 55 Years","description":"Safety profile following a single injection of MenACWY (3 lots combined) was to that following a single injection of a licensed meningococcal ACWY conjugate vaccine administered to healthy adolescents or adults (11 to 55 years of age).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1105","spread":null},{"groupId":"OG001","value":"424","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"260","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"452","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"731","spread":null},{"groupId":"OG001","value":"237","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"555","spread":null},{"groupId":"OG001","value":"183","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"533","spread":null},{"groupId":"OG001","value":"178","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Seroresponders, Ages 19 to 55 Years","description":"Immunogenicity of a single injection of Meningococcal ACWY (3 lots pooled) to that of a licensed meningococcal ACWY conjugate vaccine, defined as the percentage of subjects with seroreponse directed against N. meningitidis serogroups A, C, W, and Y (healthy subjects 19 to 55 years of Age).\n\nSeroresponse to MenACWY: For a subject with hSBA titer \\<1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with hSBA titer ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":2649},"commonTop":["Injection site pain","Headache","Myalgia","Injection site erythema","Injection site induration"]}}}